Researchers at the University of Basel and University Hospital Basel tested whether an experimental drug could activate brown fat in humans. Brown fat burns energy to generate heat, making it a key focus for obesity treatments. The trial measured both energy expenditure and brown fat activity in participants.
The results showed that the drug did raise energy expenditure, but it did not activate brown fat. This indicates the increase in energy use came from a different biological mechanism, not the hoped-for brown fat response. The finding challenges the assumption that boosting brown fat is the primary route for such drugs.
While the drug's effect on energy expenditure is real, its failure to engage brown fat raises questions about how it works and whether it will be useful for weight management. The authors note that further research is needed to identify the actual pathway and assess long-term safety and efficacy.